A family with autosomal dominant hypocalcaemia with hypercalciuria (ADHH): mutational analysis, phenotypic
C P Burren1, A Curley, P Christie
1Department of Paediatric Endocrinology, Bristol Royal Hospital for Children, United Bristol Healthcare NHS Trust, Bristol, Avon, UK. Christine.Burren@ubht.swest.nhs.uk
Insights
Autosomal dominant hypocalcaemia with hypercalciuria (ADHH) is linked to calcium-sensing receptor (CaSR) gene mutations. This study identifies a novel CaSR mutation in a family, highlighting ADHH
Area of Science:
- Endocrinology
- Genetics
- Molecular Biology
Background:
- Autosomal dominant hypocalcaemia with hypercalciuria (ADHH) is a rare genetic disorder.
- Activating mutations in the calcium-sensing receptor (CaSR) gene have been recently identified as a cause of ADHH.
Observation:
- A kindred with seven affected individuals across three generations presented with varying ages of diagnosis (birth to 50 years).
- Clinical manifestations included hypocalcaemia, hypercalciuria, low parathyroid hormone (PTH), hypomagnesaemia, and symptoms like seizures and paraesthesias.
- Complications observed were nephrocalcinosis and basal ganglia calcification.
Findings:
- DNA sequence analysis revealed a novel mutation in exon 3 of the CaSR gene (codon 129, TGC-->TAC) in all affected family members.
- This mutation resulted in the loss of a conserved cysteine residue, potentially affecting CaSR receptor dimerisation.
- The study documented significant variability in the ADHH phenotype within the family.
Implications:
- The identification of a novel CaSR mutation expands the understanding of ADHH genetics.
- The findings underscore the phenotypic variability and management complexities associated with ADHH.
- Judicious treatment is recommended to mitigate hypocalcaemic seizures while minimizing the risk of nephrocalcinosis.
Abstract:
Autosomal dominant hypocalcaemia with hypercalciuria (ADHH) is an intriguing syndrome, in which activating mutations of the calcium sensing receptor (CaSR) have recently been recognised. We describe a kindred with seven affected individuals across three generations, including patients affected in the first decade of life. Age at diagnosis varied from birth to 50 years. Affected members had hypocalcaemia (1.53-1.85 mmol/l), hypercalciuria, low but detectable parathyroid hormone (PTH) and hypomagnesaemia. Four of seven affected individuals were symptomatic (seizures, abdominal pains and paraesthesias), unrelated to severity of hypocalcaemia. Additional complications include nephrocalcinosis (n = 3) and basal ganglia calcification, identified by CT scanning in all five individuals. Symptomatic individuals were treated with calcium and calcitriol to reduce the risk of hypocalcaemic seizures. DNA sequence analysis, identified a mutation in exon 3, codon 129 (TGC-->TAC) of the CaSR gene of seven affected family members, resulting in loss of a conserved cysteine residue, potentially disrupting CaSR receptor dimerisation. Thus, a novel mutation was identified in this family, who demonstrate variability of ADHH phenotype and also illustrate the complexities of clinical management. Optimal management of ADHH is difficult and we recommend judicious treatment to avoid an increased risk of nephrocalcinosis.
More Related Videos
07:35Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
07:38Functional Characterization of Na+/H+ Exchangers of Intracellular Compartments Using Proton-killing Selection to Express Them at the Plasma Membrane
Published on: March 30, 2015
Related Concept Videos
Huntington Disease l: Introduction
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Pedigree Analysis
Sex-linked Disorders
Skeleton and Calcium Homeostasis
Genetic Lingo
